< Back to previous page
Researcher
Patrick Schöffski
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Responsible
From1 Jan 2012 → Today - Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2005 → Today
Projects
1 - 10 of 12
- Real-time qPCR platform enhancing research activities within the Laboratory of Experimental Oncology and the Laboratory of Experimental RadiotherapyFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- PhD student in preclinical research on sarcoma treatmentFrom3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Preclinical evaluation of innovative cytotoxic drugs for the treatment of soft tissue sarcomaFrom28 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Whole-genome optical mapping for comprehensive analysis of sarcoma genomes in a diagnostic settingFrom13 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the biology of translocation-related sarcomas and impact on the research for new therapy options.From1 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- CYTOTOXIC THERAPY REVISED: EXPLORATION OF INNOVATIVE (PRO)DRUGS IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMAFrom1 Sep 2018 → 25 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Molecular characterization of soft tissue sarcoma and the potential clinical applicationsFrom26 Sep 2017 → 25 Feb 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Clinical outcome, Pathological results and immunohistochemical findings of rare subtypes of soft tissue sarcomasFrom10 Aug 2015 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Establishment of new research models and in vivo efficacy testing of novel treatment strategies for resistant gastrointestinal stromal tumorsFrom1 Aug 2014 → 19 May 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting soft tissue sarcoma with smart molecules - exploring cytotoxic prodrugs and target-specific inhibitors in patient-derived xenograftsFrom1 Aug 2013 → 30 Nov 2017Funding: Nonprofit institution or equivalents
Publications
1 - 10 of 384
- Optical Genome Mapping for Comprehensive Cytogenetic Analysis of Soft-Tissue and Bone Tumors for Diagnostic Purposes.(2024)
Authors: Jef Baelen, Barbara Dewaele, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski, Daphne Hompes
Pages: 374 - 386 - Extensive surgical resections for rare pleural neoplasms: a single-center experience with a yolk sac tumor and synovial sarcoma.(2024)
Authors: Jan Van Slambrouck, Patrick Schöffski, Birgit Weynand, Raf Sciot, Yves Debaveye, Philippe Nafteux, Laurens Ceulemans
Pages: 96 - Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial(2024)
Authors: Patrick Schöffski
- Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates(2024)
Authors: Patrick Schöffski, Agnieszka Wozniak
- EWSR1::POU2AF3(COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection(2023)
Authors: Isabelle Vanden Bempt, Raf Sciot, Patrick Schöffski
- Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.(2023)
Authors: Patrick Schöffski
- A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours(2023)
Authors: Patrick Schöffski
Pages: S472 - S473 - Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours(2023)
Authors: Patrick Schöffski
- Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma(2023)
Authors: Patrick Schöffski
Pages: 3320 - 3328 - A multiplatform metabolomics approach for comprehensive analysis of GIST xenografts with various KIT mutations(2023)
Authors: Agnieszka Wozniak, Patrick Schöffski
Pages: 3883 - 3891